WordNet

reason or establish by induction
cause to arise; "induce a crisis" (同)bring_on
produce electric current by electrostatic or magnetic processes (同)induct
cause to do; cause to act in a specified manner; "The ads induced me to buy a VCR"; "My children finally got me to buy a computer"; "My wife made me buy a new sofa" (同)stimulate, cause, have, get, make
cause to occur rapidly; "the infection precipitated a high fever and allergic reactions" (同)stimulate, rush, hasten
an impairment of health or a condition of abnormal functioning
use recreational drugs (同)do drugs
administer a drug to; "They drugged the kidnapped tourist" (同)dose
a substance that is used as a medicine or narcotic
caused by or altered by or manifesting disease or pathology; "diseased tonsils"; "a morbid growth"; "pathologic tissue"; "pathological bodily processes" (同)morbid, pathologic, pathological
either of two saclike respiratory organs in the chest of vertebrates; serves to remove carbon dioxide and provide oxygen to the blood

PrepTutorEJDIC

〈人〉‘に'『勧めて』(…)『させる』 / …‘を'『引き起こす』,もたらす(cause) / 〈電気〉‘を'誘導する / …‘を'帰納する
(体の)『病気』,疾患 / (精神・道徳などの)病気,病弊
女性の話術芸人 =diseur
『薬』,薬品,薬剤 / 『麻薬』,麻酔剤 / 〈人〉‘に'薬(特に麻酔剤)を与える / 〈飲食物〉‘に'(麻酔薬・毒薬などの)薬を混ぜる
病気にかかった / 病的な,不健全な(morbid)
《しばしば複数形で》『肺』,肺臓

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 全身性抗腫瘍治療に関連する肺毒性：臨床症状、診断、および治療 pulmonary toxicity associated with systemic antineoplastic therapy clinical presentation diagnosis and treatment
2. 関節リウマチにおける薬剤誘発性肺疾患 drug induced lung disease in rheumatoid arthritis
3. 心血管系剤によって誘発された肺疾患 pulmonary disease induced by cardiovascular drugs
4. 抗腫瘍療法関連肺毒性：分子標的剤 pulmonary toxicity associated with antineoplastic therapy molecularly targeted agents
5. 関節リウマチ関連肺疾患の概要 overview of lung disease associated with rheumatoid arthritis

English Journal

Tracheobronchial lesions in eosinophilic pneumonia.

Matsuda Y1, Tachibana K2, Sasaki Y3, Tsuyuguchi K4, Kitaichi M5, Inoue Y6.Author information 1Department of Respiratory Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka 591-8555, Japan. Electronic address: ymatsuda@kch.hosp.go.jp.2Department of Respiratory Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka 591-8555, Japan; Department of Diffuse Lung Diseases and Respiratory Failure, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka 591-8555, Japan. Electronic address: ktachiba@kch.hosp.go.jp.3Department of Respiratory Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka 591-8555, Japan. Electronic address: yusasaki@kch.hosp.go.jp.4Department of Infectious Diseases, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka 591-8555, Japan. Electronic address: tsuyuguchi@kch.hosp.go.jp.5Department of Pathology, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka 591-8555, Japan. Electronic address: kitaichi@kch.hosp.go.jp.6Department of Diffuse Lung Diseases and Respiratory Failure, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka 591-8555, Japan. Electronic address: giichi@kch.hosp.go.jp.AbstractBACKGROUND: Eosinophilic pneumonia (EP) is characterized by eosinophil infiltration in the lung parenchyma. However, tracheobronchial lesions associated with the disease have been poorly described. To clarify the frequency and characteristics of cases with tracheobronchial lesions in EP, we performed a retrospective review of EP patients.
Respiratory investigation.Respir Investig.2014 Jan;52(1):21-7. doi: 10.1016/j.resinv.2013.05.006. Epub 2013 Jul 12.
BACKGROUND: Eosinophilic pneumonia (EP) is characterized by eosinophil infiltration in the lung parenchyma. However, tracheobronchial lesions associated with the disease have been poorly described. To clarify the frequency and characteristics of cases with tracheobronchial lesions in EP, we performe
PMID 24388367

Knockdown of CABYR-a/b Increases Chemosensitivity of Human Non-Small Cell Lung Cancer Cells through Inactivation of Akt.

Qian Z, Li M, Wang R, Xiao Q, Wang J, Li M, He D, Xiao X.Author information Beijing Normal University.AbstractCABYR is a calcium-binding tyrosine phosphorylation-regulated protein that was identified as a novel cancer testis (CT) antigen in lung cancer in our previous study. However, the role of CABYR as a driver of disease progression or as a chemosensitizer is poorly understood. This study sought to investigate the relationship between the expression levels of CABYR-a/b, which are the two predominant isoforms of the five isoform proteins encoded by CABYR, and chemosensitivity in non-small cell lung cancer (NSCLC) cells. We found that the shRNA-mediated knockdown of CABYR-a/b significantly inhibited the proliferation of NCI-H460 and A549 cells and resulted in the attenuation of Akt phosphorylation, which is constitutively active in lung cancer cells. The silencing of CABYR-a/b expression notably impacted the downstream components of the Akt pathways: decreasing the phospho-GSK-3β (Ser9) levels and increasing the expression of the p53 and p27 proteins. Furthermore, CABYR-a/b knockdown led to a significant increase in chemosensitivity in response to chemotherapeutic drugs and drug-induced apoptosis, both in vitro and in vivo. Conversely, the transient transfection of CABYR-a/b-depleted cells with constitutively active Akt partially restored the resistance to cisplatin and paclitaxel and significantly decreased the activation of GSK-3β and cleaved poly ADP-ribose polymerase (PARP). Taken together, our results suggest that the inhibition of CABYR-a/b is a novel method to improve the apoptotic response and chemosensitivity in lung cancer and that this CT antigen is an attractive target for lung cancer drug development. Implications: Suppression of CABYR-a/b expression increases chemosensitivity of lung cancer cells by inhibiting Akt activity.
Molecular cancer research : MCR.Mol Cancer Res.2013 Dec 20. [Epub ahead of print]
CABYR is a calcium-binding tyrosine phosphorylation-regulated protein that was identified as a novel cancer testis (CT) antigen in lung cancer in our previous study. However, the role of CABYR as a driver of disease progression or as a chemosensitizer is poorly understood. This study sought to inves
PMID 24362251

Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Baldo BA, Pham NH.Author information Molecular Immunology Unit, Kolling Institute of Medical Research, Royal North Shore Hospital of Sydney, Sydney, New South Wales, Australia, babaldo@iinet.net.au.AbstractMore than 100 drugs are used to treat the many different cancers. They can be divided into agents with relatively broad, non-targeted specificity and targeted drugs developed on the basis of a more refined understanding of individual cancers and directed at specific molecular targets on different cancer cells. Individual drugs in both groups have been classified on the basis of their mechanism of action in killing cancer cells. The targeted drugs include proteasome inhibitors, toxic chimeric proteins and signal transduction inhibitors such as tyrosine kinase (non-receptor and receptor), serine/threonine kinase, histone deacetylase and mammalian target of rapamycin inhibitors. Increasingly used targeted vascular (VEGF) and platelet-derived endothelial growth factor blockade can provoke a range of pathological consequences. Many of the non-targeted drugs are cytotoxic, suppressing haematopoiesis as well as provoking cutaneous eruptions and vascular, lung and liver injury. Cytotoxic side effects of the targeted drugs occur less often and usually with less severity, but they show their own unusual adverse effects including, for example, a lengthened QT interval, a characteristic papulopustular rash, nail disorders and a hand-foot skin reaction variant. The term hypersensitivity is widely used across a number of disciplines but not always with the same definition in mind, and the terminology needs to be standardised. This is particularly apparent in cancer chemotherapy where anti-neoplastic drug-induced thrombocytopenia, neutropenia, anaemia, vascular disorders, liver injury and lung disease as well as many dermatological manifestations sometimes have an immune basis. The most insidious of all adverse consequences of targeted therapies, however, are tumour adaptation, increased malignancy and the invasive metastatic switch seen with anti-angiogenic drugs that inhibit the VEGF-A pathway. Adverse reactions to 44 non-targeted and 33 targeted, frequently used, chemotherapeutic drugs are presented together with discussions of diagnosis, premedications, desensitizations and importance of understanding the mechanisms underlying the various drug-induced reactions. There is need for wide-ranging acceptance of what constitutes a hypersensitivity reaction and for allergists to be more involved in the diagnosis, treatment and prevention of chemotherapeutic drug-induced hypersensitivity reactions.
Cancer metastasis reviews.Cancer Metastasis Rev.2013 Dec;32(3-4):723-61. doi: 10.1007/s10555-013-9447-3.
More than 100 drugs are used to treat the many different cancers. They can be divided into agents with relatively broad, non-targeted specificity and targeted drugs developed on the basis of a more refined understanding of individual cancers and directed at specific molecular targets on different ca
PMID 24043487